Monday, December 5, 2022

1:30 PM — 2:30 PM GMT

Virtual

VIEW FULL EVENT VIDEO

Please view presentation clips in the Agenda below
Speakers are providing their own content and their opinions may not reflect that of Cytokinetics or other healthcare professionals. This content is designed for informational purposes only and is not treatment advice, guidance, or recommendations.
Full video

FACULTY

Faculty image for Ileana L Piña

Jeffrey Rothstein, MD, PhD

The John W. Griffin Director, Brain Science Institute

Professor of Neurology and Neuroscience

Director, Robert Packard Centre for ALS Research

Johns Hopkins University, School of Medicine

Faculty image for Ileana L Piña

Orla Hardiman, BSc, MB, BCh, BAO, MD, FRCPI, FAAN

Academic Unit of Neurology, Professor at Trinity College Dublin

National Clinical Lead Neurology, Trinity Biomedical Sciences Institute

Faculty image for Ileana L Piña

Jeremy M. Shefner, MD, PhD

Chief Medical Officer for Clinical Research

Barrow Neurological Institute

PROGRAM AGENDA

1:30 PM – 1:32 PM

Welcome

Stacy Rudnicki, MD

PLAY VIDEO

1:32 PM – 1:37 PM

Program Overview

Jeffrey Rothstein, MD, PhD

PLAY VIDEO

1:37 PM – 1:52 PM

Traditional Trial Design in ALS

Orla Hardiman, MD, FRCPI, FAAN

PLAY VIDEO

1:52 PM – 2:07 PM

Nontraditional Trial Design in ALS

Jeremy M. Shefner, MD, PhD

PLAY VIDEO

2:07 PM – 2:17 PM

Rebuttal: Traditional vs. Nontraditional

Orla Hardiman, MD, FRCPI, FAAN

Jeremy M. Shefner, MD, PhD

PLAY VIDEO

2:17 PM – 2:27 PM

Q&A

Moderated by Jeffrey Rothstein, MD, PhD

PLAY VIDEO

2:27 PM – 2:30 PM

Closing and Adjournment

Jeffrey Rothstein, MD, PhD

PLAY VIDEO

SLIDES

Slide resources

Rethinking Trial Design in ALS: What Are the Ideal Inclusion Criteria and Outcome Measures? A Debate

Renowned faculty will review the advantages of traditional and nontraditional outcome measures and eligibility criteria in ALS trial designs

DOWNLOAD

For questions or inquiries regarding future or past events, please contact us at alsmndinnovation@cytokinetics.com.